Nanjing Haijing Pharmaceutical Co., Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation ondansetron hydrochloride tablets (specification: 8 mg, produced by Nanjing Haijing Pharmaceutical Co., Ltd.) and the reference preparation ondansetron hydrochloride tablets (Zofran®, specification: 8 mg, produced by Novartis Pharma GmbH) in healthy subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary purpose of the study: to evaluate the safety of the test preparation ondansetron hydrochloride tablets (specification: 8 mg) and the reference preparation ondansetron hydrochloride tablets (Zofran®, specification: 8 mg) in healthy subjects.

Primary objective: To evaluate the bioequivalence of the test preparation Ezetimibe Tablets (Specification: 10 mg, Manufacturer: Nanjing Haijing Pharmaceutical Co., Ltd.) and the reference preparation Ezetimibe Tablets (Ezetimibe®, Specification: 10 mg) of which MSD Pharma (Singapore) Pte. Ltd. is the licensee in healthy male and female subjects under fasting/postprandial conditions. Secondary objective: To observe the safety of the test preparation Ezetimibe Tablets and the reference preparation Ezetimibe Tablets (Ezetimibe®) in healthy subjects.

Primary objective: To evaluate the bioequivalence of the test formulation and the reference formulation in healthy male and female subjects under fasting/fed conditions. Secondary objective: To observe the safety of the test formulation and the reference formulation in healthy subjects.